title: IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood.
authors.affiliation: Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, USA.
authors.forename: Claire Q F
authors.initials: CQF
authors.lastname: Wang
authors.affiliation: Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, USA; Rockefeller University Center for Clinical and Translational Science, New York, New York, USA.
authors.forename: Mayte
authors.initials: M
authors.lastname: Suárez-Fariñas
authors.affiliation: Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, USA.
authors.forename: Kristine E
authors.initials: KE
authors.lastname: Nograles
authors.affiliation: Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, USA.
authors.forename: Claudia A
authors.initials: CA
authors.lastname: Mimoso
authors.affiliation: Eli Lilly and Company, Lilly Research Labs, Indianapolis, Indiana, USA.
authors.forename: David
authors.initials: D
authors.lastname: Shrom
authors.affiliation: Eli Lilly and Company, Lilly Research Labs, Indianapolis, Indiana, USA.
authors.forename: Ernst R
authors.initials: ER
authors.lastname: Dow
authors.affiliation: Eli Lilly and Company, Lilly Research Labs, Indianapolis, Indiana, USA.
authors.forename: Michael P
authors.initials: MP
authors.lastname: Heffernan
authors.affiliation: Eli Lilly and Company, Lilly Research Labs, Indianapolis, Indiana, USA.
authors.forename: Robert W
authors.initials: RW
authors.lastname: Hoffman
authors.affiliation: Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, USA. Electronic address: jgk@rockefeller.edu.
authors.forename: James G
authors.initials: JG
authors.lastname: Krueger
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D002478:Cells, Cultured; D016207:Cytokines / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D020381:Interleukin-17 / Q000008:administration & dosage / Q000276:immunology / Q000494:pharmacology*; D009000:Monocytes / Q000187:drug effects* / Q000378:metabolism* / Q000473:pathology; D011565:Psoriasis / Q000188:drug therapy* / Q000378:metabolism*; D019707:Receptors, Chemokine / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D020381:Interleukin-17; D019707:Receptors, Chemokine; C549079:ixekizumab